Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ1779MR)

This product GTTS-WQ1779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.

Specifications
Product type	mRNA
Modified bases	2-Thio-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_000417.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3559
UniProt ID	P01589

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1779MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2245MR	IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	ALX-0171
GTTS-WQ11971MR	IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	MM-005
GTTS-WQ7834MR	IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	GSK 716155
GTTS-WQ7808MR	IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	GS-HIV
GTTS-WQ8751MR	IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	IBI-101
GTTS-WQ10350MR	IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	LY 3090106
GTTS-WQ13228MR	IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	PF-05082566
GTTS-WQ4610MR	IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BMS-986015

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST